



**17 February 2020**

## **UPDATE TO CAPITAL RAISING ANNOUNCEMENT**

Further to the ASX announcement on 5 February 2020, **Zelira Therapeutics Ltd (ASX:ZLD, OTCQB: ZLDAF)** is pleased to advise it has accepted additional applications from overseas investors on the same terms for the Placement ("Placement") of an additional 1,085,182 fully-paid ordinary shares at a share price of A\$0.05 to raise an additional A\$54,259 before costs from international investors. Following the acceptance of oversubscriptions, the Placement will raise A\$4,642,759 before costs ("Placement").

The Placement shares will be issued under the Company's existing 15% placement capacity under ASX Listing Rule 7.1, and accordingly will not require shareholder approval. The Placement shares are expected to be issued on Wednesday, 19 February 2020.

CPS Capital Group Pty Ltd (**CPS**) was mandated as Lead Manager to the Placement. The Placement was conducted under normal commercial terms with a fee of 6% paid to CPS.

The Company notes that Zelira Director Mr Peterson is a director and shareholder of CPS Capital Pty Ltd and may benefit from the fees received by CPS. The Board (excluding Mr Peterson) are satisfied that the fees payable to CPS are not inconsistent with fees charged for these services by other similar service providers.

This announcement has been authorised by the Board.

**Tim Slate**

**Company Secretary**

### **About Zelira Therapeutics ([www.zeliratx.com](http://www.zeliratx.com))**

Zelira Therapeutics Ltd is a leading global therapeutic medicinal cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking product development programs targeting specific conditions (e.g. HOPE™) and human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA.

The Company conducts this work in partnership with world-leading researchers and organizations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Zelira has also formed a strategic partnership with European medicinal cannabis group HAPA Pharm BV, to access HAPA Pharm's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialization for successful clinically validated formulations.

The Company has developed two proprietary formulations (HOPE™) already launched and generating revenues in Pennsylvania, has laboratory capabilities to develop formulations in Pennsylvania and Louisiana with ability to conduct clinical trials and is establishing a national footprint across the US for the licensing of its products.

###

**Address**

Level 26  
140 St Georges Terrace, Perth WA  
6000 AUSTRALIA  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: [enquiries@zeliratx.com](mailto:enquiries@zeliratx.com)  
W: [www.zeliratx.com](http://www.zeliratx.com)  
ACN 103 782 378

**Tickers**

Australia (ASX): ZLD  
USA: (OTCQB): ZLDAF

**Australia Contact**

Dr Richard Hopkins  
Managing Director & CEO, Ex USA  
+61 405 656 868  
[rhopkins@zeliratx.com](mailto:rhopkins@zeliratx.com)

Monsoon Communications  
Rudi Michelson  
+61 3 9620 3333  
[rudim@monsoon.com](mailto:rudim@monsoon.com)

**U.S. Contacts:**

Dr. Oludare Odumosu  
Managing Director & CEO, USA  
+1-909-855-0675  
[oodumosu@zeliratx.com](mailto:oodumosu@zeliratx.com)  
3553 West Chester Pike #110,  
Newtown Square, PA 19073

GVM Communications, Inc.  
Gia Morón,  
347-678-8079 |  
[gia@gvmcommsinc.com](mailto:gia@gvmcommsinc.com)